Medicare Picked Semaglutide for Price Negotiation. Here Is What Happens Next.

On January 1, 2027, Medicare starts paying $274 for a 30-day supply of Ozempic. That is not the $959 list price from 2024. It is not a generic price either, because in the United States there is no generic semaglutide on the shelf. It is a number the federal government and Novo Nordisk reached by negotiating, under the Inflation Reduction Act, over a drug that Novo still holds patents on for years.

So the medicare ozempic price, the thing people actually type into search boxes, is $274 per 30-day supply starting in 2027. The same price covers Wegovy and Rybelsus, which are also semaglutide. The patent watchdog group I-MAK notes that the three drugs “were included in the second round of Medicare drug price negotiations under the Inflation Reduction Act.” The facts do not settle how that price will interact with the generics lined up for the early 2030s. That is the interesting part.

What Medicare will pay for Ozempic starting in 2027

DrugPatentWatch says the negotiated figure “represents a 71% reduction from the 2024 list price of $959.” I write about money, which means my main professional skill is dividing one number by another and then acting surprised. So let me do that. $274 divided by $959 is about 0.286. Medicare will pay a bit more than a quarter of the sticker price. For a patented drug. For a drug family that, per IQVIA, did $26 billion in combined Ozempic and Wegovy sales in 2024 while growing about 40% a year.

And look at the number itself. It is not $275, which is the number a person would pick. It is not $250, which is the number a person would ask for. It is $274, the number you get when two large institutions with spreadsheets argue for a long time and nobody wants to round. It works out to about $9.13 a day (I checked twice). It has the specific, slightly tired quality of a price that both sides can explain to their bosses.

Why bother negotiating if generics are coming anyway

Here is the sensible objection. Drugs go generic. Patents expire, competitors pile in, prices fall, and that is the system working as designed. Semaglutide’s US compound patent runs to around 2031 or 2032. Why have the government haggle over a drug that the normal process will cheapen on its own in five years or so?

This is a fair point, and the evidence from elsewhere sort of supports it. In India, more than 40 generic semaglutide brands launched on March 21, 2026, the day after patent expiry. About ten days later Novo cut the Indian price of Ozempic by 36% and Wegovy by 48%. That is what generic entry is supposed to do, and it did it fast. (The India story has its own article on this site; the short version is “a lot of companies, all at once.”)

But the mechanism in the US is stranger than the objection assumes. For this particular kind of drug, in this particular country, the negotiation produced a discount that is bigger than what generic entry has usually produced. The point is that waiting for generics might not have gotten Medicare to $274 at all.

When generics can actually show up in the US

The compound patent, US 8,129,343, was extended through patent term restoration to December 5, 2031. Novo Nordisk’s 2025 Form 20-F gives 2032 as the US compound expiry for Ozempic, Rybelsus and Wegovy. Then there are the secondary patents (there are always secondary patents). One titled “Semaglutide in medical therapy” covers Ozempic and runs to October 10, 2038. Another on cardiovascular conditions runs to April 28, 2037. Others cover the pen, oral dosing, etc.

The generic makers are already queued up. On April 10, 2026, Apotex got the first FDA tentative approval for a generic Ozempic. “Tentative” is the operative word, since the patents still stand in the way. Under the Hatch-Waxman Act, a brand company can trigger an automatic 30-month stay of generic approval by listing patents in the FDA’s Orange Book (a list of things a company would like protected, and companies differ in how much they feel needs protecting). The country-by-country dates live in another article. For Medicare, what matters is that the earliest plausible generic window sits years after the $274 price takes effect.

What generic entry does to the price of a drug like this

India’s numbers are dramatic, but India started from a different place. In the US, the track record for peptide drugs is more modest. Prost Biotech writes that US generic peptide drugs typically get only 15 to 40% price reductions, compared with 80 to 90% for small-molecule generics, “due to the more expensive biosimilar approval pathway.” Making a copy of a complicated molecule is expensive, and the copier wants to be paid for the trouble.

The nearest example is semaglutide’s older sibling. When Teva launched generic Victoza in the US, it was priced at $469.60 for a two-pack against roughly $560 for the brand. That is a 16 to 17% discount, with more competition expected later. It’s fine. It is just not 71%.

How a negotiated price and a generic price collide

Here is a hypothetical, entirely made up, using Victoza-style math. It is 2032, and a generic maker launches semaglutide at 16% off the old $959 list price. That comes to about $805. At the full 40% from the top of the typical range, it is about $575. Both numbers are well above $274.

Picture the launch meeting. “Hey guys, great news, we’re coming in at a 16% discount.” “A discount to what?” “To the price nobody in Medicare pays.” Push it further. The generic salespeople pitch Medicare on an identical molecule at three times the price, Medicare politely declines, and the generic maker cuts again. Eventually someone launches “generic semaglutide, now only slightly more expensive than the brand,” which is a dumb product to sell. That is about how it feels when the outlet store marks things down from the original tag while the main store is already running a bigger sale.

The real world probably won’t go like that, and the facts here do not say how it will go. They do not settle whether the negotiated price holds once generics arrive, or what US generic makers will actually charge. The point of the hypothetical is just that the usual order (brand price high, generic price low) can flip when the government negotiates the brand down first.

And everyone involved is behaving reasonably. Medicare is a huge buyer and was never going to wait until 2032 for relief. Novo, I guess, would rather take a negotiated price it can plan around than an uncertain one. Generic makers face an expensive approval pathway and need to price against something, so they price against the brand.

What the savings estimates say

A study re-estimating Medicare spending on semaglutide for 2026 through 2035 puts base-case savings at $463 million under the negotiated price. Combine Most Favored Nation pricing with generic entry assumptions and the figure rises to $2.63 billion (which is what happens when a model gets two wishes instead of one). Set against $26 billion in sales in a single year, $463 million over ten years is not a huge number. For instance, it averages about $46 million a year.

Why a 71% headline cut produces savings that small is not something these facts explain. The study’s assumptions do that work, and I don’t have them. What the range does show is that the people modeling it think generic timing still matters a great deal, on top of the negotiation, not instead of it.

So back to the $274. In 2027 Medicare starts paying it for a brand-name drug. Somewhere around 2032 generics may arrive, priced off a list price that Medicare stopped paying years earlier. Medicare’s first cheap semaglutide will be Novo’s own.